Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Accumulated Expenses (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Accumulated Expenses for 10 consecutive years, with $32.4 million as the latest value for Q1 2022.

  • On a quarterly basis, Accumulated Expenses rose 0.56% to $32.4 million in Q1 2022 year-over-year; TTM through Jan 2022 was $32.4 million, a 0.56% increase, with the full-year FY2022 number at $32.4 million, up 0.56% from a year prior.
  • Accumulated Expenses was $32.4 million for Q1 2022 at Usana Health Sciences, up from $32.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $33.7 million in Q4 2018 to a low of $26.2 million in Q4 2019.
  • A 4-year average of $31.1 million and a median of $32.3 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 47.13% in 2018, then decreased 22.41% in 2019.
  • Usana Health Sciences' Accumulated Expenses stood at $33.7 million in 2018, then fell by 22.41% to $26.2 million in 2019, then grew by 23.07% to $32.2 million in 2021, then increased by 0.56% to $32.4 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Accumulated Expenses are $32.4 million (Q1 2022), $32.2 million (Q1 2021), and $26.2 million (Q4 2019).